Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Eligard (Leuprolide Acetate) Prostate Cancer Products Approved in Canada FORT COLLINS, CO -- November 10, 2003 -- Atrix Laboratories, Inc. (Nasdaq: ATRX) announced that Sanofi-Synthelabo Canada, Atrix's licensee, has received notice of compliance (NOC) from the Therapeutic Products Directorate of Health Canada for Eligard® 7.5mg and 22.5mg (leuprolide acetate for injection), one- and three-month sustained-release prostate cancer products. NOC permits these products to be sold in Canada. Sanofi-Synthelabo Canada will be responsible for marketing the products in Canada. "As director of technical affairs, it is my responsibility to leverage our core U.S. New Drug Application to build a worldwide franchise for Eligard," said Elyse Wolff, director of technical affairs. "This is the first ex-U.S. approval and we look forward to repeating this success throughout the world." The Canadian market opportunity for hormone therapy products for prostate cancer is approximately $60 million with a similar competitive landscape as the U.S. Sustained levels of leuprolide decreases testosterone levels to suppress tumor growth in patients with prostate cancer. The liquid Eligard products, using Atrix's proprietary Atrigel® sustained-release drug delivery technology, are injected subcutaneously with a small gauge needle, forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed. Eligard 30mg, four-month prostate cancer product is currently under review by Health Canada. Eligard 7.5mg, 22.5mg and 30mg products for advance prostate cancer are currently marketed in the U.S. by Sanofi-Synthelabo, Inc. Eligard 7.5mg and 22.5mg, like other hormonal treatments for prostate cancer, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment. Response to these products should be monitored by measuring serum Eligard® is a registered trademark of Sanofi-Sythelabo. SOURCE: Atrix Laboratories, Inc. E-mail this page to a friend or colleague! To print, use this version